|In Hospital||30 Day||1 Year||2 Year||3 Year|
|MI (CK-MB > 3X ULN)||9.3%||9.7%||10.6%||10.9%||11.2%|
|Kaplan-Meier method used to estimate 30-day to three-year event rates. Certain one- and two-year rates updated at three-year data extract.|
Recent publications have indicated that women are an under-studied population in PCI clinical studies. At SCAI, Dr. Chambers presented the results of an ORBIT II gender sub-analysis in addition to the main three-year results. He concluded, "In the ORBIT II trial, similar rates of MACE through three years post-procedure exist in both males and females. This is significant, and an example of CSI's thoroughness when conducting clinical studies."More information about the ORBIT II study design is available at www.ClinicalTrials.gov. About Coronary Artery Disease (CAD)CAD is a life-threatening condition and a leading cause of death in men and women in the United States. CAD occurs when a fatty material called plaque builds up on the walls of arteries that supply blood to the heart. The plaque buildup causes the arteries to harden and narrow (atherosclerosis), reducing blood flow. The risk of CAD increases if a person has one or more of the following: high blood pressure, abnormal cholesterol levels, diabetes, or family history of early heart disease. According to the American Heart Association, 16.3 million people in the United States have been diagnosed with CAD, the most common form of heart disease. Heart disease claims more than 600,000 lives in the United States each year. According to estimates, significant arterial calcium is present in nearly 40 percent of patients undergoing a percutaneous coronary intervention (PCI). Significant calcium contributes to poor outcomes and higher treatment costs in coronary interventions when traditional therapies are used, including a significantly higher occurrence of death and major adverse cardiac events (MACE). About Cardiovascular Systems, Inc.Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital Atherectomy System in peripheral arteries in August 2007. In October 2013, the company received FDA approval for the use of the Diamondback Orbital Atherectomy System in coronary arteries. To date, over 249,000 of CSI's devices have been sold to leading institutions across the United States. For more information, visit the company's website at www.csi360.com.